Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids
Adult
Medicine (General)
Indoles
extracellular matrix
Activin Receptors, Type II
Cell Cycle Proteins
Smad2 Protein
03 medical and health sciences
R5-920
0302 clinical medicine
Cell Line, Tumor
nintedanib
Humans
Hippo Signaling Pathway
uterine fibroids
Research Articles
Cell Proliferation
verteporfin
Leiomyoma
Hippo signaling
Integrin beta1
Verteporfin
Middle Aged
Extracellular Matrix
3. Good health
collagenase
Microbial Collagenase
Uterine Neoplasms
Female
Antifibrotic Agents
Transcription Factors
DOI:
10.1002/ctm2.475
Publication Date:
2021-07-04T14:39:08Z
AUTHORS (8)
ABSTRACT
AbstractBackgroundUterine fibroids are highly prevalent, collagen‐rich, mechanically stiff, fibrotic tumors for which new therapeutic options are needed. Increased extracellular matrix (ECM) stiffness activates mechanical signaling and Hippo/YAP promoting fibroid growth, but no prior studies have tested either as a therapeutic target. We tested the hypothesis that injection of a purified form of collagenase Clostridium histolyticum (CCH) that selectively digests type I and type III collagens would alter ECM stiffness, Hippo signaling, and selectively reduce fibroid cell growth. We also used two FDA‐approved drugs, verteporfin and nintedanib, to elucidate the role of Hippo/YAP signaling in uterine fibroid and myometrial cells.MethodsThe clinical trial was registered (NCT02889848). Stiffness of samples was measured by rheometry. Protein expression in surgical samples was analyzed via immunofluorescence. Protein and gene expression in uterine fibroid or myometrial cell lines were measured by real time PCR and western blot, and immunofluorescence.ResultsInjection of CCH at high doses (0.1–0.2 mg/cm3) into fibroids resulted in a 46% reduction in stiffness in injected fibroids compared to controls after 60 days. Levels of the cell proliferation marker proliferative cell nuclear antigen (PCNA) were decreased in fibroids 60 days after injection at high doses of CCH. Key Hippo signaling factors, specifically the transcriptionally inactive phosphorylated YAP (p‐YAP), was increased at high CCH doses, supporting the role of YAP in fibroid growth. Furthermore, inhibition of YAP via verteporfin (YAP inhibitor) decreased cell proliferation, gene and protein expression of key factors promoting fibrosis and mechanotransduction in fibroid cells. Additionally, the anti‐fibrotic drug, nintedanib, inhibited YAP and showed anti‐fibrotic effects.ConclusionsThis is the first report that in vivo injection of collagenase into uterine fibroids led to a reduction in Hippo/YAP signaling and crucial genes and pathways involved in fibroid growth. These results indicate that targeting ECM stiffness and Hippo signaling might be an effective strategy for uterine fibroids.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (69)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....